Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
Birth Weight | Birth Weight | MTC | Horikoshi | 2013 | NA | 26836 | 5.00e-2 | 3.12e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 5.00e-2 | 2.22e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 1.00e-2 | 6.44e-3 |
Head Circumference | Head Circumference | MTC | Taal | 2012 | NA | 10768 | 1.00e-3 | 3.72e-2 |
Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 1.00e-2 | 1.53e-2 |
Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 1.00e-3 | 3.58e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 5.00e-2 | 1.01e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 1.00e-2 | 1.30e-4 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 1.00e-3 | 4.04e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-5 | 3.71e-2 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 3.26e-2 |
Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 5.00e-2 | 2.91e-2 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-2 | 4.49e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 3.52e-2 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 3.75e-2 |
BMI Physical Activity Interaction | BMI Inactive European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 2.84e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 8.43e-3 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-2 | 2.08e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-3 | 1.67e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-4 | 1.67e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 30 to 45 | MTC | Medina-Gomez | 2018 | NA | 10062 | 1.00e-3 | 4.54e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 30 to 45 | MTC | Medina-Gomez | 2018 | NA | 10062 | 1.00e-5 | 4.90e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density Under 15 | MTC | Medina-Gomez | 2018 | NA | 11807 | 1.00e-3 | 3.82e-3 |
Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 5.00e-2 | 1.81e-2 |
Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 1.00e-2 | 9.68e-4 |
Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.86e-2 |
Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.21e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 1.00e-2 | 7.87e-4 |
Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 2.46e-2 |
Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 1.00e-2 | 6.82e-3 |
Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 1.00e-3 | 4.90e-2 |
Insulin Secretion | Disposition Index Adjusted For BMI | MTC | Wood | 2017 | NA | 2042 | 1.00e-2 | 1.61e-2 |
Kidney Function | CKDi | MTC | Gorski | 2015 | NA | 45530 | 1.00e-3 | 2.97e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 2.04e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-2 | 4.02e-2 |
Loneliness | Case Control | MTC | Gao | 2017 | 1632 | 3164 | 5.00e-2 | 3.22e-2 |
Loneliness | Loneliness | MTC | Gao | 2017 | NA | 6924 | 5.00e-2 | 3.19e-2 |
Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 4.65e-2 |
TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 4.17e-2 |
Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.51e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 1.22e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 2.04e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 9.38e-3 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 1.00e-4 | 2.97e-2 |
Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 5.00e-2 | 6.67e-3 |
Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.46e-2 |
AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 1.00e-3 | 3.87e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 3.33e-2 |
Facial attractiveness | Facial attractiveness, male raters | ETC | Hu | 2019 | NA | 3928 | 5.00e-2 | 1.17e-2 |
Facial attractiveness | Facial attractiveness, male raters | ETC | Hu | 2019 | NA | 3928 | 1.00e-2 | 9.22e-3 |
Facial attractiveness | Facial attractiveness, female raters | ETC | Hu | 2019 | NA | 3928 | 5.00e-2 | 4.14e-2 |
Facial attractiveness | Facial attractiveness, female raters | ETC | Hu | 2019 | NA | 3928 | 1.00e-2 | 8.17e-3 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 5.00e-2 | 1.39e-2 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 6.96e-3 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 9.22e-3 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-5 | 1.56e-2 |
BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 1.00e-3 | 2.95e-2 |
Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-5 | 4.84e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-2 | 3.23e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.37e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-3 | 2.71e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 6.55e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.46e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 5.31e-3 |
Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 5.00e-2 | 2.61e-2 |
Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 4.94e-2 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 3.12e-2 |
Lung function | Lung function (forced vital capacity) variance | ETC | Wang H | 2019 | NA | 317,222 | 1.00e-3 | 2.89e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 1.13e-4 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 2.96e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-3 | 4.79e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 4.60e-2 |
COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 1.00e-2 | 4.34e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.